Safety and Efficacy of the Bispecific T-Cell Engager (BiTE) as Conditioning Regimen for ABO-incompatible Living Donor Kidney Transplantation

Conditions : ABO Blood Type Incompatible Kidney Transplantation Interventions : Drug: Blinatumomab Treatment; Drug: Teclistamab treat Sponsors : West China Hospital Not yet recruiting